Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO
Aurinia Pharmaceuticals (AUPH) has granted its Chief Financial Officer, Michael S. Hearne, 116,144 performance stock units (PSUs) and 70,230 employee stock options. The PSUs are performance-based, vesting in tranches upon the company's shares reaching specific target prices and time-based conditions, while the stock options have a strike price of $15.28 and expire in 2036. This compensation is detailed in a recent Form 4 SEC filing, indicating it as an equity award rather than an open-market transaction.
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units
Aurinia Pharmaceuticals Inc.'s Chief Legal Officer, Stephen P. Robertson, was granted 115,541 performance stock units as part of his compensation. These units, awarded at no cash cost, will vest in two tranches over three and five years, contingent on Aurinia’s stock price reaching specific target levels significantly above the grant-date price. This transaction increases his direct holdings to 621,402 common shares or share-based units.
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options
Aurinia Pharmaceuticals Inc.'s Chief Operating Officer, Ryan Cole, was granted 116,144 performance stock units (PSUs) and 70,230 stock options. These equity awards are compensation-related, with the PSUs vesting based on share-price targets and time-based conditions, and the stock options having an exercise price of $15.28 per share and expiring in 2036. No open-market share purchases or sales were reported in this filing.
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has successfully completed its tender offer for Kezar Life Sciences, with 80.24% of Kezar's outstanding shares tendered, exceeding the required majority threshold. The offer, supported by Information Agent Alliance Advisors, provided Kezar stockholders with $6.955 in cash per share plus a contingent value right. This transaction, valued at approximately $41.2 million, highlights Alliance Advisors' expertise in facilitating complex tender offers in the biopharmaceutical sector.
Tangible book value per share of Aurinia Pharmaceuticals Inc. – FWB:IKAP
The article provides information on the tangible book value per share of Aurinia Pharmaceuticals Inc. (FWB:IKAP) as listed on the Frankfurt Stock Exchange via TradingView. It indicates that the market was closed at the time of publication and there were no trades. The core content is limited to the headline and a brief mention of 'Period Value Change Change %'.
Behavioral Patterns of AUPH and Institutional Flows
This article analyzes behavioral patterns and institutional flows for Aurinia Pharmaceuticals Inc (AUPH), providing AI-generated trading strategies. It highlights a strong near-term sentiment influencing neutrality mid-term and a long-term positive bias, noting an exceptional 49.0:1 risk-reward setup. The analysis includes detailed entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies across multiple timeframes.
Aurinia Pharmaceuticals (AUPH) Price Target Increased by 34.15% to 16.03
This article reports that Aurinia Pharmaceuticals (AUPH) has seen its average analyst price target increase by 34.15% to $16.03. This new average target suggests a potential upside of 152.05% from its current price. The analysts' consensus indicates a "Strong Buy" rating for AUPH.
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions
Aurinia Pharmaceuticals' recent robust earnings did not lead to a stock surge, raising questions among investors. The company's accrual ratio of 1.16 indicates significantly weaker free cash flow compared to its profit, partly due to a one-off tax benefit of US$164 million. This suggests that the reported statutory profits might be of "low quality" and could give an overly positive impression, potentially dropping if the tax benefit isn't repeated.
Aurinia Pharmaceuticals Inc - Common Shares (NQ: AUPH)
This article provides a list of recent press releases from Aurinia Pharmaceuticals Inc. (AUPH). The releases cover topics such as regulatory filings for voclosporin in Europe, board appointments, annual general meeting results, clinical study data presentations, investor conference participation, patient navigation grant programs, and financial results. The information highlights the company's activities related to its lupus nephritis treatment, LUPKYNIS™ (voclosporin).
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences By Investing.com
Aurinia Pharmaceuticals has successfully acquired Kezar Life Sciences, with the transaction finalizing after a tender offer where Aurinia's subsidiary obtained approximately 80.24% of Kezar's common shares. Kezar shareholders received $6.955 in cash per share plus one contingent value right, leading to Kezar becoming a wholly-owned subsidiary of Aurinia. The merger was executed under Delaware General Corporation Law, bypassing a separate stockholder vote.
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals announced the completion of its acquisition of Kezar Life Sciences, with its U.S. subsidiary acquiring approximately 80.24% of Kezar's outstanding common shares. Kezar shareholders received $6.955 in cash per share and one contingent value right (CVR). Following the tender offer, Kezar became a wholly owned subsidiary of Aurinia Pharma U.S., Inc. through a merger.
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Q1 2026 Earnings Beat
Aurinia Pharmaceuticals reported strong Q1 2026 earnings, with revenues of US$77.71 million and net income of US$34.36 million, both exceeding previous year figures. The company's stock has seen an 86.7% return over the past year and is currently trading below the $17 analyst target, suggesting it may be undervalued. This performance is attributed to improved operational efficiency, including gross margin expansion and increased operating leverage.
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences By Investing.com
Aurinia Pharmaceuticals Inc. has announced the completion of its acquisition of Kezar Life Sciences, Inc. The transaction, finalized after a tender offer where Aurinia acquired 80.24% of Kezar's shares for cash and a contingent value right (CVR), makes Kezar a wholly owned subsidiary of Aurinia. This merger was conducted under Section 251(h) of Delaware law, meaning no separate stockholder vote was required.
AUPH (NASDAQ: AUPH) Proposed sale of 717,688 common shares
A Form 144 SEC filing by Aurinia Pharmaceuticals Inc. (AUPH) indicates a proposed sale of 717,688 common shares. This transaction is associated with the exercise of options under a registered plan, with an indicated trade date of May 11, 2026, and a cash sale method. The filing provides details on the securities to be sold, the acquisition transaction, and key figures related to the proposed sale.
500,503 AUPH shares listed for resale by Morgan Stanley (NASDAQ: AUPH)
Morgan Stanley Smith Barney LLC Executive Financial Services has filed a Form 144 notice indicating a planned resale of 500,503 shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) common stock. The filing, dated May 11, 2026, states these shares are related to an exercise of options under a registered plan and have an aggregate value of $7,927,967.52. This is a routine regulatory notice and does not detail the exact timing or execution method of the sale.
Danske Bank A S Cuts Stake in Aurinia Pharmaceuticals Inc $AUPH
Danske Bank A/S significantly reduced its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 95.3% in the fourth quarter, selling 72,820 shares and retaining only 3,600 shares valued at $57,000. This comes as Director Kevin Tang increased his holdings by 4.56% through a purchase of over half a million shares. Aurinia Pharmaceuticals reported strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $17.25.
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aurinia Pharmaceuticals Inc. recently beat analyst revenue and statutory earnings per share (EPS) estimates, with Q1 revenue reaching US$32 million and EPS at US$0.02. Despite this outperformance, analysts have slightly decreased their revenue forecasts for 2026 and subsequent years, maintaining a neutral outlook on the company's future stock performance. The article suggests that while the recent results are positive, investors should consider the broader analyst sentiment and the potential for a more significant price movement.
Aurinia Pharmaceuticals (AUPH) Is Up 6.3% After Stronger Q1 LUPKYNIS-Driven Profitability Has The Bull Case Changed?
Aurinia Pharmaceuticals reported strong Q1 2026 results, with revenue of US$77.71 million and net income of US$34.36 million, driven by LUPKYNIS sales for lupus nephritis. This performance strengthens the near-term investment case, but the company faces risks associated with single-product reliance amid competition and pricing pressures. Aurinia's acquisition of Kezar Life Sciences signals a move towards diversification, which is crucial for future growth catalysts beyond LUPKYNIS.
Aurinia Pharmaceuticals (AUPH) Q1 EPS Of US$0.26 Tests Bullish Margin Narratives
Aurinia Pharmaceuticals reported Q1 2026 revenue of US$77.7 million and basic EPS of US$0.26, following a year of sharp earnings growth and a 100% net margin. While bulls highlight high trailing profitability, concerns exist regarding earnings quality and the sustainability of current margins, especially as consensus forecasts predict average earnings declines despite revenue growth. The company's low P/E ratio relative to its industry and DCF fair value reflects this mixed sentiment, driven by both opportunities and concerns over margin compression and reliance on non-cash items.
Aurinia Pharmaceuticals Sees 2026 Rev $315M-$325M >AUPH
Aurinia Pharmaceuticals announced its revenue guidance for 2026, projecting sales of $315 million to $325 million. This financial outlook provides insight into the company's expected performance in the coming years.
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals announced its financial results for Q1 2026, reporting a total revenue of $77.7 million, a 24% increase from the previous year, and net product sales of LUPKYNIS at $73.6 million, up 23%. The company also achieved a net income of $34.4 million and diluted earnings per share of $0.25, while reiterating its full-year 2026 revenue guidance of $315 million to $325 million. Aurinia continues to focus on developing therapies for autoimmune diseases and advancing LUPKYNIS as a standard-of-care treatment for lupus nephritis.
AUPH: Aurinia Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides a detailed financial overview of Aurinia Pharmaceuticals Inc. (AUPH), including its stock price, market capitalization, P/E ratio, and recent earnings performance. It highlights key financial metrics, recent news, and bullish/bearish sentiments surrounding the company, emphasizing its strong product sales growth and significant management changes.
Aurinia Pharmaceuticals (AUPH) Is Up 6.3% After Stronger Q1 LUPKYNIS-Driven Profitability Has The Bull Case Changed?
Aurinia Pharmaceuticals (AUPH) reported stronger-than-expected Q1 2026 results, driven by increased LUPKYNIS sales, with revenue reaching US$77.71 million and net income US$34.36 million. While LUPKYNIS's performance strengthens the near-term outlook, the company's dependence on a single product and the acquisition of Kezar Life Sciences highlight a strategic move towards diversification. The article suggests investors consider both the strong Q1 results and the long-term risks associated with LUPKYNIS dependence and pipeline integration to form their own investment verdict.
Aurinia: Q1 Earnings Snapshot
Aurinia Pharmaceuticals Inc. (AUPH) reported stronger-than-expected first-quarter earnings of $34.4 million, or 25 cents per share, surpassing analyst estimates. The biotechnology company also exceeded revenue forecasts with $77.7 million and projects full-year revenue between $315 million and $325 million. Aurinia's stock has performed well, rising 2% year-to-date and more than doubling over the past 12 months.
Aurinia (NASDAQ: AUPH) boosts Q1 profit, buys back stock and moves to acquire Kezar
Aurinia Pharmaceuticals reported a strong Q1 2026, with net income surging to $34.4 million on increased LUPKYNIS sales and a higher gross margin. The company also repurchased 2.5 million shares for $36.8 million and announced a definitive agreement to acquire Kezar Life Sciences for $6.955 per share plus a contingent value right, aiming to expand its autoimmune and oncology assets. This comes amidst significant executive leadership changes, with a new CEO, COO, and CFO appointed in March 2026.
Aurinia (NASDAQ: AUPH) boosts Q1 profit, cash flow and reaffirms 2026 outlook
Aurinia Pharmaceuticals reported strong financial results for Q1 2026, with total revenue increasing 24% to $77.7 million and net income rising 48% to $34.4 million. The company also saw a significant improvement in operating cash flow to $32.6 million and reaffirmed its 2026 revenue guidance of $315–$325 million. These results were primarily driven by strong LUPKYNIS net product sales and strategic share repurchases.
Aurinia: Q1 Earnings Snapshot
Aurinia Pharmaceuticals Inc. (AUPH) reported strong first-quarter earnings, with net income of $34.4 million, or 25 cents per share, surpassing Wall Street's expectation of 18 cents per share. The biotechnology company also exceeded revenue forecasts, posting $77.7 million against an expected $77.4 million, and projects full-year revenue between $315 million and $325 million. Aurinia's stock has performed well, rising 2% year-to-date and more than doubling over the last 12 months.
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals reported strong financial results for the three months ended March 31, 2026, with total revenue up 24% to $77.7 million and net income increasing 48% to $34.4 million. The company reaffirmed its 2026 revenue and net product sales guidance, projecting continued growth. Key drivers include increased sales of LUPKYNIS and growing collaboration revenue, alongside progress in developing aritinercept for multiple autoimmune indications.
Aurinia: Q1 Earnings Snapshot
Aurinia Pharmaceuticals Inc. (AUPH) reported strong first-quarter earnings and revenue, surpassing Wall Street expectations. The biotechnology company achieved $34.4 million in earnings, or 25 cents per share, on revenue of $77.7 million. Aurinia also provided a positive outlook, projecting full-year revenue between $315 million and $325 million, and noted a significant increase in its stock value over the past year.
(AUPH) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting a weak near-term sentiment but strong long-term outlook. It details three institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry zones, targets, and stop losses. The analysis also includes a multi-timeframe signal breakdown for near, mid, and long-term horizons, indicating potential price movements and risk-reward scenarios.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Analysts
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus "Hold" rating from six analysts, with an average one-year price target of $17.25. The company recently reported strong quarterly results, exceeding EPS expectations, and Insider Kevin Tang increased his stake. Despite insider buying and solid financials, analysts maintain a cautious stance.
Short Interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Decreases By 15.7%
Short interest in Aurinia Pharmaceuticals (NASDAQ:AUPH) declined by 15.7% in April, totaling 9,112,230 shares, which represents about 7.8% of its shares sold short. This brings the days-to-cover ratio to 8.4 days. A director, Kevin Tang, recently increased his stake by purchasing over 500,000 shares, and institutional investors also made significant moves, with insiders now owning 12.20% of the company.
Aurinia earnings on deck: Can new leadership sustain growth?
Aurinia Pharmaceuticals (NASDAQ: AUPH) is set to release its first-quarter earnings, marking the initial results under new CEO Kevin Tang. Investors will be closely watching revenue trajectory, LUPKYNIS adoption, Tang's strategic vision, and the integration of the pending Kezar Life Sciences acquisition. Analysts expect 19 cents per share on $75.29 million in revenue, which would represent year-over-year growth but a sequential decline from the previous quarter.
Aurinia earnings on deck: Can new leadership sustain growth? By Investing.com
Aurinia Pharmaceuticals is set to report its first-quarter earnings, the first under new CEO Kevin Tang, with analysts expecting 19 cents per share on $75.29 million revenue. Investors are closely watching revenue trajectory, LUPKYNIS adoption, Tang's strategic vision, and the integration of the pending Kezar Life Sciences acquisition. Despite expected sequential revenue decline, Aurinia remains a profitable biotech player with growth expectations, a healthy gross profit margin, and a recent history of topping forecasts.
Aurinia earnings on deck: Can new leadership sustain growth?
Aurinia Pharmaceuticals is set to report its first-quarter earnings under new CEO Kevin Tang, with analysts expecting 19 cents per share on $75.29 million revenue. Investors will closely watch LUPKYNIS adoption, Tang's strategic vision, and the integration of the Kezar Life Sciences acquisition as the company navigates a competitive and growing lupus nephritis market.
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’
This article reports on a lawsuit filed against Dr. Peter Stein, a former FDA drug review chief, by Aurinia Pharma shareholders. The lawsuit alleges that Stein manipulated the approval process for Aurinia's lupus nephritis drug, Lupkynis, for personal financial gain. This legal action comes amidst broader concerns about potential conflicts of interest at the FDA and has led to accusations of stock manipulation from retail traders.
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’
This article discusses the ongoing turmoil at the FDA, which has now impacted Aurinia Pharma. A lawsuit has been filed against a former FDA drug review chief, leading to accusations of "stock manipulation" from retail traders.
Aurinia Pharmaceuticals stock hits 52-week high at $16.72 By Investing.com
Aurinia Pharmaceuticals Inc. (AUPH) stock reached a 52-week high of $16.72, currently trading at $16.74, marking a 102.72% increase over the past year. The company boasts a market capitalization of $2.18 billion and a P/E ratio of 7.73, with InvestingPro suggesting it is undervalued with a fair value of $20.87. Recent positive developments include the acquisition of Kezar Life Sciences Inc. and strong financial results for Q4 2025, along with a new CEO appointment.
Aurinia Pharmaceuticals stock hits 52-week high at $16.72
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock recently achieved a 52-week high of $16.72, showing a 102.72% increase over the past year. This surge, backed by a market capitalization of $2.18 billion and a P/E ratio of 7.73, reflects strong investor confidence and comes seven days before earnings. The company recently acquired Kezar Life Sciences Inc. for $6.955 per share and reported strong Q4 2025 financial results, including EPS of $1.53 and revenue of $77.1 million.
Aurinia Pharmaceuticals (Nasdaq:AUPH) - Stock Analysis
Aurinia Pharmaceuticals (AUPH) is a biopharmaceutical company focused on autoimmune diseases, currently trading at a 5.1% discount to its estimated fair value with a market cap of US$2.2 billion. While revenue is projected to grow by 11.83% annually, earnings are forecast to decline by 3% per year for the next three years. The stock has shown strong past performance with a 99.3% increase over the last year, but faces risks from declining earnings forecasts and perceived high non-cash earnings.
Tudor Investment Corp ET AL Buys Shares of 65,964 Aurinia Pharmaceuticals Inc $AUPH
Tudor Investment Corp ET AL has acquired 65,964 shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) in the third quarter, valued at approximately $729,000, representing about 0.05% of the company. Additionally, Director Kevin Tang increased his direct holdings by purchasing 516,439 shares for $7.225 million. Aurinia Pharmaceuticals reported strong quarterly earnings, significantly beating analyst estimates for both EPS and revenue.
AUPH Earnings History & Surprises | EPS & Revenue Results | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH)
This article provides a detailed historical overview of Aurinia Pharmaceuticals Inc.'s (AUPH) quarterly earnings, including EPS and revenue actuals, analyst estimates, and surprise percentages. It highlights the company's consistent performance in beating EPS estimates over the last four quarters and provides insights into future earnings expectations. The page also features historical Q2Q growth trends for both EPS and Revenue, along with analysis of beat statistics.
Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 12-Month High - Here's What Happened
Aurinia Pharmaceuticals (NASDAQ:AUPH) recently hit a new 52-week high of $16.54, driven by strong quarterly earnings where the company reported $1.53 EPS against an expected $0.21 and revenue of $77.11 million. Director Kevin Tang further increased his stake in the company by acquiring over 500,000 shares. Analysts maintain a "Hold" rating on the stock with a consensus target price of $17.25.
Trading Systems Reacting to (AUPH) Volatility
Quantitative Research Desk reports that Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is experiencing volatility, with trading systems reacting to near-term neutral sentiment amidst mid and long-term strength. The analysis highlights an exceptional risk-reward short setup and provides institutional trading strategies tailored with distinct risk profiles and holding periods, including position trading, momentum breakout, and risk hedging strategies.
AUPH - Aurinia Announces Results of Annual General Meeting
Aurinia Pharmaceuticals Inc. announced the results of its annual general meeting held on June 21, 2018. All eight incumbent directors were re-elected with overwhelming support, and other proposals, including the appointment of auditors, were also approved. The company is clinical stage and focuses on developing therapies for diseases like lupus nephritis, FSGS, and dry eye syndrome, primarily with its investigational drug, voclosporin.
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks
Aurinia Pharmaceuticals is acquiring Kezar Life Sciences to expand its autoimmune disease portfolio, specifically adding the clinical candidate zetomipzomib. This acquisition aims to diversify Aurinia's revenue base beyond its single commercial product and build a broader autoimmune franchise, though it introduces execution risks related to integration and increased R&D spending. Investors will be watching how Aurinia manages the integration, updates development plans, and potentially adjusts its financial guidance.
AUPH Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for AUPH (Aurinia Pharmaceuticals Inc.), detailing past quarterly results and future forecasts. It highlights analyst estimates for upcoming quarters, emphasizing the relationship between earnings forecast revisions and stock price movements. The report also includes historical stock price reactions around earnings announcements and addresses frequently asked questions about AUPH's financial performance.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2025 Earnings Call Transcript
This document is a transcript of the Q3 2025 earnings call for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). It provides a detailed record of the discussions held during the call, including financial results, operational updates, and potentially questions and answers with analysts.
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Its Recent Leadership Overhaul
Aurinia Pharmaceuticals (AUPH) has undergone a significant leadership change, appointing Kevin Tang as CEO, Michael Hearne as CFO, and Ryan Cole as COO, with several new executives tied to Tang Capital Management. Despite a strong one-year return of nearly 100%, the stock's current price of $15.61 suggests it is undervalued, with a fair value estimate of $17.00. This valuation is supported by operational efficiency, share repurchases, and strong cash flow, though risks like patent disputes and pipeline execution remain.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Analysts
Aurinia Pharmaceuticals Inc (AUPH) has received a consensus "Hold" recommendation from analysts, with an average one-year target price of $17.25. The company recently surpassed Q4 earnings and revenue expectations, reporting an EPS of $1.53 against an estimated $0.21. Insider activity shows Director Kevin Tang acquiring a significant number of shares, increasing his stake by approximately 4.56%.
